JP Morgan Chase’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.7M | Buy |
240,102
+89,298
| +59% | +$5.08M | ﹤0.01% | 2289 |
|
|
2025
Q4 | $6.38M | Buy |
150,804
+150,785
| +793,605% | +$8.44M | ﹤0.01% | 3099 |
|
|
2025
Q3 | $1.08K | Sell |
19
-101
| -84% | -$3.34K | ﹤0.01% | 6982 |
|
|
2025
Q2 | $3.1K | Sell |
120
-32,630
| -100% | -$366K | ﹤0.01% | 6473 |
|
|
2025
Q1 | $334K | Sell |
32,750
-46,116
| -58% | -$603K | ﹤0.01% | 5009 |
|
|
2024
Q4 | $1.1M | Buy |
78,866
+17,979
| +30% | +$317K | ﹤0.01% | 4566 |
|
|
2024
Q3 | $1.19M | Buy |
60,887
+40,404
| +197% | +$770K | ﹤0.01% | 4363 |
|
|
2024
Q2 | $381K | Buy |
20,483
+20,441
| +48,669% | +$431K | ﹤0.01% | 4830 |
|
|
2024
Q1 | $589 | Hold |
42
| – | – | ﹤0.01% | 6697 |
|
|
2023
Q4 | $357 | Sell |
42
-2,407
| -98% | -$18.2K | ﹤0.01% | 6968 |
|
|
2023
Q3 | $21.9K | Buy |
2,449
+1,974
| +416% | +$19K | ﹤0.01% | 6049 |
|
|
2023
Q2 | $4.09K | Sell |
475
-15,024
| -97% | -$160K | ﹤0.01% | 6206 |
|
|
2023
Q1 | $163K | Buy |
15,499
+2,765
| +22% | +$83.7K | ﹤0.01% | 5176 |
|
|
2022
Q4 | $433K | Sell |
12,734
-2,641
| -17% | -$128K | ﹤0.01% | 4612 |
|
|
2022
Q3 | $738K | Sell |
15,375
-29,063
| -65% | -$1.73M | ﹤0.01% | 4230 |
|
|
2022
Q2 | $2.53M | Buy |
44,438
+32,262
| +265% | +$2.04M | ﹤0.01% | 3345 |
|
|
2022
Q1 | $985K | Buy |
12,176
+7,564
| +164% | +$1.12M | ﹤0.01% | 4278 |
|
|
2021
Q4 | $935K | Sell |
4,612
-10,941
| -70% | -$2.37M | ﹤0.01% | 4443 |
|
|
2021
Q3 | $4.19M | Sell |
15,553
-102
| -0.7% | -$24.5K | ﹤0.01% | 3181 |
|
|
2021
Q2 | $4.03M | Buy |
15,655
+647
| +4% | +$179K | ﹤0.01% | 3248 |
|
|
2021
Q1 | $4.5M | Buy |
15,008
+3,258
| +28% | +$1.01M | ﹤0.01% | 3058 |
|
|
2020
Q4 | $3M | Sell |
11,750
-2,327
| -17% | -$601K | ﹤0.01% | 3197 |
|
|
2020
Q3 | $3.57M | Sell |
14,077
-112
| -0.8% | -$35.2K | ﹤0.01% | 2828 |
|
|
2020
Q2 | $4.93M | Buy |
14,189
+1,904
| +15% | +$594K | ﹤0.01% | 2470 |
|
|
2020
Q1 | $3.29M | Sell |
12,285
-110,266
| -90% | -$34.1M | ﹤0.01% | 2592 |
|
|
2019
Q4 | $39.7M | Buy |
122,551
+7,732
| +7% | +$2.24M | 0.01% | 1093 |
|
|
2019
Q3 | $31.4M | Buy |
114,819
+14,701
| +15% | +$5.39M | 0.01% | 1249 |
|
|
2019
Q2 | $52.1M | Sell |
100,118
-44,917
| -31% | -$22.5M | 0.01% | 934 |
|
|
2019
Q1 | $73.1M | Buy |
145,035
+27,414
| +23% | +$16.2M | 0.01% | 778 |
|
|
2018
Q4 | $58M | Buy |
117,621
+10,491
| +10% | +$6.33M | 0.01% | 844 |
|
|
2018
Q3 | $98M | Sell |
107,130
-35,488
| -25% | -$30.3M | 0.02% | 698 |
|
|
2018
Q2 | $104M | Buy |
142,618
+58,157
| +69% | +$67.1M | 0.02% | 644 |
|
|
2018
Q1 | $135M | Sell |
84,461
-22,597
| -21% | -$29.1M | 0.03% | 530 |
|
|
2017
Q4 | $95.9M | Sell |
107,058
-47,898
| -31% | -$28.3M | 0.02% | 673 |
|
|
2017
Q3 | $55M | Buy |
154,956
+4,703
| +3% | +$1.47M | 0.01% | 877 |
|
|
2017
Q2 | $44.1M | Sell |
150,253
-36,908
| -20% | -$10.7M | 0.01% | 977 |
|
|
2017
Q1 | $65.9M | Buy |
187,161
+108,256
| +137% | +$24.3M | 0.02% | 815 |
|
|
2016
Q4 | $14.5M | Buy |
78,905
+32,173
| +69% | +$6.54M | ﹤0.01% | 1676 |
|
|
2016
Q3 | $12M | Sell |
46,732
-11,484
| -20% | -$2.96M | ﹤0.01% | 1668 |
|
|
2016
Q2 | $12.4M | Sell |
58,216
-1,260
| -2% | -$282K | ﹤0.01% | 1711 |
|
|
2016
Q1 | $12.3M | Sell |
59,476
-8,694
| -13% | -$1.67M | ﹤0.01% | 1655 |
|
|
2015
Q4 | $17.2M | Buy |
68,170
+4,490
| +7% | +$923K | ﹤0.01% | 1441 |
|
|
2015
Q3 | $10.5M | Sell |
63,680
-557
| -0.9% | -$98.5K | ﹤0.01% | 1725 |
|
|
2015
Q2 | $12.1M | Sell |
64,237
-238,877
| -79% | -$41.1M | ﹤0.01% | 1789 |
|
|
2015
Q1 | $50M | Sell |
303,114
-21,021
| -6% | -$4.32M | 0.01% | 899 |
|
|
2014
Q4 | $75.4M | Buy |
324,135
+28,890
| +10% | +$6.17M | 0.02% | 742 |
|
|
2014
Q3 | $53.5M | Buy |
295,245
+2,442
| +0.8% | +$467K | 0.01% | 861 |
|
|
2014
Q2 | $56.3M | Sell |
292,803
-10,124
| -3% | -$1.79M | 0.01% | 797 |
|
|
2014
Q1 | $55.1M | Buy |
302,927
+183,137
| +153% | +$36.2M | 0.02% | 759 |
|
|
2013
Q4 | $20.4M | Sell |
119,790
-7,875
| -6% | -$1.27M | 0.01% | 1319 |
|
|
2013
Q3 | $20M | Sell |
127,665
-14,120
| -10% | -$2.61M | 0.01% | 1332 |
|
|
2013
Q2 | $24.6M | Buy |
+141,785
| New | +$21.7M | 0.01% | 1129 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
JP Morgan Chase's NKTR Position: Q1 2026 in Review
JP Morgan Chase increased its Nektar Therapeutics (NKTR) stake by 59% in Q1 2026, buying an estimated $5.08M and bringing the position to 240,102 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.
JP Morgan Chase first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $135M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- JP Morgan Chase held 240,102 shares of Nektar Therapeutics worth $15.7M as of Q1 2026.
- JP Morgan Chase bought 89,298 Nektar Therapeutics shares in Q1 2026, an estimated $5.08M.
- Nektar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2289 holding.
- JP Morgan Chase first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Nektar Therapeutics position peaked at $135M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.